In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

Vertex Pharmaceuticals remains a buy, anchored by its dominant cystic fibrosis (CF) franchise and optionality in JOURNAVX. VRTX's near-term growth hinges on JOURNAVX's commercial ramp and pivotal ...

We recently published 10 Big Names Bleed Double Digits. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the worst-performing stocks on Tuesday. Vertex Pharmaceuticals nosedived on Tuesday to hit a ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...

Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of ...

Vertex SME Holdings Limited, a private equity vehicle managed by JMMB Securities Limited, is gearing up to raise another $1 billion to fund its pipeline of investment opportunities. Private equity is ...

Vertex Pharmaceuticals Incorporated remains a Buy: its cystic fibrosis franchise ensures robust revenue for a decade, and its pipeline offers multiple long-term growth drivers. Casgevy's long-term ...

Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs as ...

Boston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR Therapeutics to develop the first CRISPR treatment approved by the U.S.